This study also demonstrated that baricitinib treatment reduced mRNA expression of multiple IFN responsive genes and consistently suppressed two key cytokines implicated in SLE pathogenesis, IL-12p40 and IL-6 [28]. This evidence concerns the gene IL6 and systemic lupus erythematosus.